Immunovant, Inc.

    Jurisdiction
    United States
    ISIN
    US45258J1025 (IMVT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. Read full profile

    Fundamentals

    Net revenue
    €136.47K
    Gross margin
    -16.9%
    EBIT
    -€28.10M
    EBIT margin
    -20,589.4%
    Net income
    -€381.53M
    Net margin
    -279,564.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€428.34M +12.3%
    €21.90M -€459.09M +7.2%
    €117.02M +434.2% -€460.24M +0.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Geffner Michael Chief Medical Officer -2.4K $18.15 -$43.29K
    Stout Jay S Chief Technology Officer -2.8K $18.15 -$50.91K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Andreas Halvorsen 1.1M $19.05M -292K Sell
    Peter Brown 396K $6.77M +315K Buy

    Earnings Calls

    Latest earnings call: June 9, 2022 (Q4 2022)

    Add to watchlist

    Notifications